TACSTD2 Human
Description
TACSTD2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 267 amino acids (31-274a.a.) and having a molecular mass of 29.9kDa. TACSTD2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
TROP2 was initially identified as a biomarker of invasive trophoblast cells and later found to be expressed in various types of cancer cells, as well as in different organs during development and in adult stem cells during homeostasis . The protein is also referred to as EpCAM 2 due to its structural and functional similarities with the epithelial cell adhesion molecule (EpCAM) .
TACSTD2 is involved in several key biological processes:
- Cell Proliferation and Migration: It participates in cell cycle progression through the activation of the MAPK signaling pathway .
- Neovascularization: In non-small-cell lung cancer, TROP2 has been shown to regulate neovascularization by activating the ERK1/2 signaling pathway .
- Cell Adhesion and Signal Transduction: As a cell surface receptor, TROP2 plays a role in cell self-renewal, proliferation, and transformation .
TACSTD2 has been implicated in the development and progression of various human tumors. For instance, its hypermethylation is associated with aggressive cancer characteristics in renal cell carcinoma (RCC), lung adenocarcinoma, hepatocellular carcinoma, and cholangiocarcinoma . In RCC, higher methylation levels of TACSTD2 are significantly associated with advanced disease, high tumor stage, and the presence of metastases .
Given its role in tumor progression and neovascularization, TACSTD2 is a potential target for cancer therapy. Inhibiting its function could provide novel anti-angiogenesis strategies for treating cancers such as non-small-cell lung cancer . Additionally, the methylation status of TACSTD2 could serve as a biomarker for the prognosis and diagnosis of certain cancers .
